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Background.Althoughpulmonaryhypertensioncomplicatingdilatedcardiomyopathyhasbeenshowntobeasigniﬁcantriskfactor
for graft failure after heart transplantation, the upper limits of pulmonary vascular resistance (PVR) that would contraindicate
pediatric heart transplantation are not known. Methods. A retrospective review of all pediatric orthotopic heart transplant
(OHT) performed at our institution from 2002 to 2007 was performed. Seven patients with PVR > 6 Wood’s units (WU)
prior to transplant were compared pre- and postoperatively with 20 matched controls with PVR < 6 WU. All pulmonary
vasodilator therapies used are described as well as outcomes during the ﬁrst year posttransplant. Results. The mean PVR prior
to transplantation in the 7 study cases was 11.0±4.6 (range 6–22) WU, compared to mean PVR of 3.07±0.9 WU (0.56–4.5) in the
controls (P = .27×10
−6). All patients with elevated PVR were treated pre-OHT with either Sildenaﬁl or Bosentan. Post-OHT, case
patients received a combination of sildenaﬁl, iloprost, and inhaled nitric oxide. All 7 case patients survived one year post-OHT,
andtherewasnostatisticaldiﬀerencebetweencasesandcontrolsforhospitalstay,rejection/readmissions,orgraftrightventricular
failure. Mean PVR in the cases at one and three months post-OHT was not signiﬁcantly diﬀerent between the two groups. Only
one of the cases required prolonged treatment with iloprost after OHT. Conclusions. A PVR above 6 WU should not be an absolute
contraindication to heart transplantation in children.
1.Introduction
Children with cardiomyopathies often develop elevated
pulmonary vascular resistance due to chronic left ventricular
dysfunction and elevated left atrial pressures. Elevated
pulmonary pressures add a signiﬁcant risk factor to heart
grafts exposed to donor brain death and ischemia during
transport to the recipient. Preexisting pulmonary hyper-
tension has been shown in numerous studies to be a risk
factor for increased mortality after (OHT) [1–7]. Previous
retrospective studies on larger cohorts of pediatric patients
have shown up to 75% incidence of right ventricular failure
with 15% mortality after transplant in patients with pre-
OHT PVR > 6 Wood’s Units (WU), compared to a 20%
incidence of right heart failure in those without preoperative
elevated PVR [8, 9]. Case reports in both the pediatric and
adult populations have shown that treatment pre-OHT with
therapies for pulmonary hypertension can lower PVR and
allow for safe transplantation [10–12].
A number of treatment modalities are now available to
treat pulmonary arterial hypertension. Intravenous nitro-
prusside and prostacyclin, and inhaled nitric oxide have
proven valuable for both assessment and perioperative treat-
ment in heart transplant candidates [13–15]. Unfortunately,
many cardiomyopathy patients may need treatment for
pulmonary hypertension for extended periods both before
and after heart transplantation. The newer oral treatments
for pulmonary hypertension, bosentan and sildenaﬁl, have
not been well evaluated in pediatric patients. In the adult
population, bosentan has been shown to lower PVR to levels2 Journal of Transplantation
acceptable for heart transplantation, and one case report
has shown that these patients can go on to be successfully
transplanted [12]. Additionally, bosentan has been shown
to signiﬁcantly improve six-minute walk distances in adults
with pulmonary hypertension [16]. Clearly, there is a
signiﬁcant advantage of orally administered medications for
the chronic care of transplant patients. Many are on the
waiting list of pre-OHT as outpatients and require home
medication at hospital discharge post-OHT. Bosentan is
an oral nonselective endothelin receptor antagonist, well
established as a treatment in the pediatric population
for idiopathic pulmonary hypertension. Its clinical beneﬁt
usually requires 3 months treatment, and its clinical eﬀects
have been mostly studied after 3 months of therapy [12, 17–
21]. Sildenaﬁl inhibits phosphodiesterase type 5 (PDE-5) in
smooth muscle of the pulmonary vasculature. It has been
showntobebeneﬁcialinpediatricsforidiopathicpulmonary
hypertension [22–25], persistent pulmonary hypertension
of the newborn [26–28], and for pulmonary hypertension
related to congenital heart disease [29–34].
Furthermore, approximately 7% [35]o fc h i l d r e nr e c e i v -
ing a transplant require ventricular assist devices, which
by unloading the left heart also lower pulmonary pressures
associated with cardiomyopathies and left atrial hyperten-
sion. Numerous studies have proven beneﬁcial eﬀects of pre-
OHT VAD placement for lowering PVR and allowing for
transplantation [36–38].
This study reviews the initial experience with sildenaﬁl
and bosentan in addition to post-operative inhaled nitric
oxide for pediatric cardiomyopathy patients with elevated
pulmonary vascular resistance before and after orthotopic
heart transplantation.
2. Methods
2.1. Patients. After obtaining Institutional Review Board
approval, all patients undergoing OHT from 2002 to 2007
were retrospectively reviewed. During this time period,
sildenaﬁl and/or bosentan was used for all pediatric OHT
patients with PVR > 6 WU indexed to body-surface area.
Pre-operative and post-operative data was obtained for all
patients including: age, weight, height, body-surface area,
diagnosis, PVR (pre and post OHT), donor weight, resolu-
tion and recurrence of pulmonary hypertension, length of
hospital stay, length of post-OHT medical treatment, graft
rejection, deaths, echocardiographic data, and catheteriza-
tion data. All PVR data are given in WU and are indexed
to body surface area. Outcome data for 7 patients with
elevated pre-operative PVR was compared to outcomes of 20
patients with normal pre-operative PVR transplanted during
the same time period at UCLA Medical Center. The pre-
OHT catheterization data closest to the time of transplant
was compared to data at 1 week to 1 month, 3 months, and
one-year post-OHT (see Table 1).
2.2. OHT/PVR Management. All of the patients with ele-
vated PVR at pre-OHT catheterization were admitted to
the ICU and treated with inotropes and diuretics; four of
these patients underwent testing for response of PVR to
administration of nitric oxide (NO). After OHT, immuno-
suppression consisted of tacrolimus (Prograf, Astellas, Deer-
ﬁeld, IL) mycophenolate mofetil (Cell-Cept Roche, Basel),
and a prednisone taper. The steroid dosing was 2mg/kg
intravenous every eight hours times 3 doses, then 1mg/kg
divided twice a day weaned over two weeks to 1/2mg/kg
divided twice a day. Prednisone was weaned to oﬀ over the
ﬁrst year in low-risk patients without rejection. Prednisone
was maintained at a low dose in presensitized patients with
elevated panel reactive antibodies, and pulses were given to
patients with rejection episodes.
Bosentan (Actelion Pharmaceuticals, San Francisco, CA)
or sildenaﬁl (Pﬁzer, New York, NY) was used to treat pre-
transplant pulmonary hypertension. Treatment was begun
after catheterization in all patients with PVR > 6, and
length of treatment depended on waiting time for OHT.
Bosentan was chosen for patients who had symptoms and a
diagnosis greater than 3 months or lower than 1b transplant
waiting list status while sildenaﬁl was given to those with
shorter expected diagnosis to transplant times. Patients were
treated with either sildenaﬁl and/or tracleer for an average
of 56 days prior to receiving OHT (range 15–171 days).
Sildenaﬁl dosing was 0.5mg/kg/dose orally three times a
day, titrated to 1mg/kg/dose as tolerated. Bosentan dosing
was 62.5mg orally twice a day for patients under 40kg,
and 125mg for patients over 40kg. Bosentan was not
used post-OHT because of the potential for elevated blood
levels due to interaction with tacrolimus. Liver function
tests were checked monthly in patients receiving bosentan.
Nitric oxide (NO) was used in all case patients in the
immediate postoperative period in the intensive care unit
a sap r o p h y l a c t i cm e a s u r e .N Ow a sb e g u na td o s e so f5 –
10ppmandweanedoﬀpriortoextubation.Onepatientwith
persistent pulmonary. hypertension after OHT was treated
with inhaled iloprost (Ventavis. Actelion Pharmaceuticals,
San Francisco, CA), 5mcg six times per day.
2.3. Statistics. Statistical analysis was performed by com-
paring continuous variables using Student’s t-test with
Microsoft Excel (Microsoft Corp., Redmond, WA). P-values
of less than .05 were considered signiﬁcant.
3. Results
3.1. Pre-OHT. The seven patients with pulmonary hyper-
tension ranged from 4–18 years at the time of starting
pulmonary vasodilator therapy. Four were females. Pre-
operative diagnoses included four with dilated cardiomy-
opathy (DCM) and three with restrictive cardiomyopathy
(RCM). The comparison group included 5 males and 15
females, ages 1–19, all of whom had pre-op PVR < 5W U .
Diagnoses of the comparison group included 19 with DCM,
and one that developed cardiomyopathy after mitral valve
replacement for Shone’s complex. The mean PVR prior to
transplantation in the 7 study cases was 11.0 ± 4.6 (range 6–
22)WU,comparedtomeanPVRof3.07 ± 0.9WU(0.6–4.5)
in the controls (P = .27 ×10
−6).Journal of Transplantation 3
Table 1
Patients Males Females Weight at Pre-OHT Days pre-OHT on Pre-OHT Pre-OHT Pre-OHT Mean Pre-OHT
time of OHT (kg) Dx vasodilator tx PVR TPG PAP (mmHg) PCWP (mmHg)
Cases 3 4 30.8 3 RCM 56 11 15.3 45 28.3
(11.6–53.7) 4 DCM (15–171) (6–22) (9–21) (30–57) (20–38)
Controls 5 15 34.9 19 DCM — 3.07 6.3 24.2 17.9
(7–70) 1 Shone’s Complex (0.6–4.5) (4–10) (14–45) (8–36)
Four of the patients with pulmonary hypertension were
tested pre-OHT for PVR reactivity with oxygen and NO at
catheterization. Three of these patients had <2W Ud e c r e a s e
in PVR, while one with RCM decreased from 13 WU to 8
WU. Three cases were not tested for PVR reactivity prior to
OHT.
Five of the cases with pulmonary hypertension (four
with DCM and one with RCM) were treated pre-OHT with
sildenaﬁl (ranging from 10–87 days of treatment), and the
three with RCM with bosentan (90–240 days treatment).
One patient with RCM, an 18-year-old female, was treated
pre-OHT with both medications. Three of the 7 pulmonary
hypertension cases with DCM (including the one with PVR
of 13 WU) were bridged to OHT with a ventricular assist
device: ECMO (n = 2; for 3 and 10 days pre-OHT) or a
biventricular assist device (n = 1; for 2.5 months pre-OHT).
3.2. Post-OHT. All 7 cases survived one year post-OHT.
There were no readmissions for RV failure. The comparison
group had a 90% survival at one year, with two deaths as
ar e s u l to fs e v e r eg r a f tr e j e c t i o n( P = .8). Average hospital
stay for the 7 case patients was longer than for the control
group (31.3 days, versus 19 days for the controls). Measures
of cardiac function were similar 1-2 weeks postoperatively
with no signiﬁcant diﬀerence in the following clinical data
between cases and controls: thermodilution cardiac index
(3.2lpm/m2 versus 2.5lpm/m2)( P = .14), pulmonary
capillary wedge pressure (12mmHg versus 13mmHg) (P =
.86), left ventricular ejection fraction estimated by m-mode
and Simpson’s rule with 2-dimensional echocardiography
(62.5% versus 62%) (P = .64) (see Table 2).
Mean PVR in the cases at one month post-OHT was
4.6 ± 1.8 WU (1.6–6.9 WU) compared to 2.4 ± 1.4 WU
(0.5–6.9) in the comparison group (P = .002). At 3 months
post-OHT, the mean PVR of the case group was 4.1 ± 2.6
(2.3–10) compared to 3.3 ± 1.9 (0.5–7) in the comparison
group (P = .42). At the 3-month time point, four of the 7
pulmonary hypertension patients had PVR less than 4 WU.
Atoneyear,themeanPVRforthecasepatientswas3.5 ± 1.5
WU (2.6–5.4; n = 5) compared to 2.8 ± 1.8 WU (0.8–4.7),
(P = .2) (see Figure 1). One control patient had a PVR at
1 and 3 months of 6.9 WU that decreased to below 3 WU
by 6 months. This patient initially had a low-cardiac output
requiring signiﬁcant inotropic support thatrecoveredduring
the second week post-OHT, but did not receive treatment for
pulmonary hypertension.
Sildenaﬁl treatment was initiated postoperatively in
the four cases with pre-OHT minimally-reactive PVR. At
3 months post-OHT, these patients had a PVR of 3.6, 3.6,
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5.9, and 7.5 WU. Sildenaﬁl was weaned oﬀ by 6 months in
3 patients once the PVR was less than 3 WU. By one year,
the patient with PVR of 10 WU at 3 months had a PVR of
5.4 WU. This patient had a pre-OHT diagnosis of RCM and
wastreated240dayswithbosentanpreoperatively.Therehad
been an 8-year interval between initial diagnosis and OHT.
This patient was started on inhaled iloprost at 6 months
post-OHT, in addition to sildenaﬁl. At 2 years post-OHT, she
had a PVR less than 2 WU and her iloprost and sildenaﬁl
were stopped. There were no observed interactions between
sildenaﬁlandiloprostwithimmunosuppressivemedications,
and no signiﬁcant side-eﬀects.
4. Discussion
The successful heart transplantation of seven pediatric
cardiomyopathypatientswithpulmonaryhypertensionasso-
ciated with left heart failure is reported. All case patients
had PVR > 6 WU at pre-OHT catheterization, tolerated
medical treatments, and had no signiﬁcant post-OHT graft
failure.
The elevated PVR in all of these cardiomyopathy patients
was likely secondary to the direct eﬀects of elevated left atrial
pressures on the pulmonary vascular bed [39]. Improvement
in pulmonary pressures post-OHT may be attributed to a
decrease in left ventricular diastolic pressures with increased
cardiac output of the functional left ventricle of the donor4 Journal of Transplantation
Table 2
Patients Post OHT Post OHT (1-2 wk) Post OHT (1-2 wk) Post OHT (1-2 wk)
Hospital stay (days) C.I. (L/min/m2) LV EF% PCWP (mmHg)
Cases 31.3 3.2 62.5 12
Control 19 2.5 62 13
heart. However, during the time from development of the
cardiomyopathy to heart transplantation, vascular remod-
eling of the pulmonary bed may occur and pulmonary
hypertension may progress [40]. Pre-existing pulmonary
hypertension is known to lead to increased mortality due to
graft right heart failure [8, 9], with the peri-operative period
being a high-risk time for pulmonary hypertensive episodes
and right heart graft failure. In fact, a recent study looking
at patients undergoing transplantation with pre-operative
elevated PVR had a 75% incidence of post-operative RV
failure, as compared to a 20% in those without elevated PVR
[9]. This, we feel, makes a strong argument for the use of
pulmonary vasodilators in patients with elevated pulmonary
vascular resistance pretransplantation, and perhaps the use
of post-operative inhaled nitric oxide and oral pulmonary
vasodilators as well.
As expected, patients with long standing pulmonary
hypertension may take longer to recover a normal PVR after
OHT. One patient described here went 9 years between the
diagnosis of a restrictive cardiomyopathy and heart trans-
plantation. She had persistently elevated PVR after OHT.
Thispatienthadpersistentpulmonary hypertensionupto12
months post-OHT, despite normal left ventricular function
and hemodynamics. By 2 years post-OHT, the pulmonary
hypertension resolved and she is now oﬀ all pulmonary
vasodilators.TheotherpatientswithadiagnosisofRCMhad
shorter periods with pulmonary hypertension prior to OHT,
but required treatment 3–6 months after transplantation.
Aside from the patient with RCM mentioned above, the
patients with DCM and RCM did not have signiﬁcant
diﬀerences in recovery of PVR or hospital stay. In fact, two
of the patients bridged with ECMO had post-OHT hospital
stays longer than 1 month. The longer hospital stays were
likely to have been a function of other postsurgical issues
rather than elevated PVR.
Cardiomyopathy patients expected to have long waiting
times for a donor were treated with bosentan. Sildenaﬁl
is more appropriate in the peri-operative period due to
its more rapid eﬀects on the pulmonary vasculature. We
now use sildenaﬁl, along with nitric oxide in the immediate
post-operative period for patients with pre-existing pul-
monary hypertension. Cyclosporine, a calcineurin inhibitor,
is thought to raise the blood levels of bosentan, and thus
increase the risk of liver damage [41]. Because tacrolimus
is also a calcineurin inhibitor and a part of our standard
immunosuppression regimen, we have not used bosentan
post-OHT. We did not observe any side eﬀects or adverse
interactions between these medications and the immuno-
suppressive medications our patients were taking. Finally,
mechanical support has been shown also to reduce PVR,
making transplantation a successful option, and three of
our patients with DCM and pulmonary hypertension were
bridged to heart transplantation with assist devices.
Limitations of this study include the small sample size
andtheretrospectivenatureofthestudy.Ideally,suchastudy
wouldincludepatientswithelevatedPVRthatdidnotreceive
pulmonary vasodilators for comparison to treatment cases;
however, this has not been possible due to the small number
of patients at a single institution. Additionally, the control
patients who underwent heart transplantation during the
same period as the study patients nearly all had dilated
cardiomyopathy, whereas three of the seven study patients
had a diagnosis of restrictive cardiomyopathy. Although
all of our study patients did well posttransplantation, this
is a distinction between our study and control patients
worth noting. Three of our 7 study patients were not
tested for PVR reactivity prior to starting of pulmonary
vasodilator therapy, which is another consequence of the
limited available data in this retrospective study. Further-
more, three of our 7 study patients were placed on an
assist device (in addition to receiving pulmonary vasodilator
therapy) prior to transplantation. Therefore, successful heart
transplantation in these three patients cannot be completely
attributedtoplacingthemonpulmonaryvasodilatortherapy
alone, and the role of ventricular assist devices in selecting
patients with respect to successful heart transplantation
n e e d st ob ei n v e s t i g a t e df u r t h e r .A n dﬁ n a l l y ,o u rs t u d y
group consisted of seven patients with cardiomyopathy and
pulmonary venous hypertension who ultimately received
heart transplantation successfully with the aid of pulmonary
vasodilators. The same, however, may not hold true for other
conditions and other forms of pulmonary hypertension,
and so further research is warranted on these patients and
pulmonary vasodilator therapy. In summary, although this
small retrospective study contains numerous limitations,
recent pulmonary vasodilator therapies, in conjunction with
other treatment modalities, present the prospect for heart
transplantation in the pediatric population. More studies in
the pediatric population, with a larger sample size and of
a prospective nature, are required to study these promising
therapies and their role in heart transplantation in the
future.
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